CStone Pharmaceuticals

SEHK:2616 Stock Report

Market Cap: HK$7.0b

CStone Pharmaceuticals Future Growth

Future criteria checks 5/6

CStone Pharmaceuticals is forecast to grow earnings and revenue by 76.7% and 45.4% per annum respectively. EPS is expected to grow by 84.6% per annum. Return on equity is forecast to be -4% in 3 years.

Key information

76.7%

Earnings growth rate

84.57%

EPS growth rate

Biotechs earnings growth32.4%
Revenue growth rate45.4%
Future return on equity-4.00%
Analyst coverage

Low

Last updated25 Jul 2026

Recent future growth updates

Analysis Article • Mar 29

CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Have Been Cutting Their Estimates

The investors in CStone Pharmaceuticals 's ( HKG:2616 ) will be rubbing their hands together with glee today, after the...

Recent updates

Analysis Article • Mar 29

CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Have Been Cutting Their Estimates

The investors in CStone Pharmaceuticals 's ( HKG:2616 ) will be rubbing their hands together with glee today, after the...
Analysis Article • Sep 26

CStone Pharmaceuticals' (HKG:2616) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The CStone Pharmaceuticals ( HKG:2616 ) share price has softened a substantial 26% over the previous 30 days, handing...
Analysis Article • Jul 07

What CStone Pharmaceuticals' (HKG:2616) 33% Share Price Gain Is Not Telling You

Despite an already strong run, CStone Pharmaceuticals ( HKG:2616 ) shares have been powering on, with a gain of 33% in...
Analysis Article • Jun 18

Shareholders May Not Be So Generous With CStone Pharmaceuticals' (HKG:2616) CEO Compensation And Here's Why

Key Insights CStone Pharmaceuticals' Annual General Meeting to take place on 25th of June CEO Jason Yang's total...
Analysis Article • May 23

CStone Pharmaceuticals' (HKG:2616) 35% Price Boost Is Out Of Tune With Revenues

CStone Pharmaceuticals ( HKG:2616 ) shares have had a really impressive month, gaining 35% after a shaky period...
Analysis Article • Apr 08

Revenues Working Against CStone Pharmaceuticals' (HKG:2616) Share Price Following 35% Dive

CStone Pharmaceuticals ( HKG:2616 ) shares have had a horrible month, losing 35% after a relatively good period...
Analysis Article • Apr 01

Analysts Are More Bearish On CStone Pharmaceuticals (HKG:2616) Than They Used To Be

One thing we could say about the analysts on CStone Pharmaceuticals ( HKG:2616 ) - they aren't optimistic, having just...
Analysis Article • Feb 14

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise

CStone Pharmaceuticals ( HKG:2616 ) shares have continued their recent momentum with a 28% gain in the last month...
Analysis Article • Dec 12

Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Oct 04

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise

CStone Pharmaceuticals ( HKG:2616 ) shares have continued their recent momentum with a 29% gain in the last month...
Analysis Article • May 12

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

Those holding CStone Pharmaceuticals ( HKG:2616 ) shares would be relieved that the share price has rebounded 27% in...
Analysis Article • Mar 04

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

To the annoyance of some shareholders, CStone Pharmaceuticals ( HKG:2616 ) shares are down a considerable 28% in the...
Analysis Article • Jan 18

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

CStone Pharmaceuticals ( HKG:2616 ) shares have retraced a considerable 25% in the last month, reversing a fair amount...

Earnings and Revenue Growth Forecasts

SEHK:2616 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,1039370-613
12/31/20271,71368774-634
12/31/2026479-2432-1354
12/31/2025270-437-328-328N/A
9/30/2025236-407-359-359N/A
6/30/2025202-377-430-430N/A
3/31/2025305-234-387-387N/A
12/31/2024407-91-303-303N/A
9/30/2024432-117-293-369N/A
6/30/2024457-142-284-435N/A
3/31/2024460-255-360-512N/A
12/31/2023464-367-437-589N/A
9/30/2023472-559-487-548N/A
6/30/2023481-750-537-508N/A
3/31/2023481-827-625-559N/A
12/31/2022481-903-713-611N/A
9/30/2022454-1,205-966-841N/A
6/30/2022426-1,508-1,219-1,072N/A
3/31/2022335-1,714-1,426-1,278N/A
12/31/2021244-1,920-1,633-1,484N/A
9/30/2021681-1,622-1,241-1,103N/A
6/30/20211,118-1,324-848-722N/A
3/31/20211,079-1,272-714-615N/A
12/31/20201,039-1,221-580-508N/A
9/30/2020519-1,482-971-920N/A
6/30/2020-2-1,744-1,362-1,333N/A
3/31/2020-1-1,906-1,227-1,207N/A
12/31/2019N/A-2,069-1,091-1,081N/A
9/30/201911-1,688N/A-898N/A
6/30/201912-1,246N/A-699N/A
3/31/201912-858N/A-745N/A
12/31/201813-470N/A-791N/A
9/30/201813-336N/A-679N/A
12/31/201710-107N/A-240N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2616 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3%).

Earnings vs Market: 2616 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2616 is expected to become profitable in the next 3 years.

Revenue vs Market: 2616's revenue (45.4% per year) is forecast to grow faster than the Hong Kong market (8.6% per year).

High Growth Revenue: 2616's revenue (45.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2616 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/03 23:06
End of Day Share Price 2026/08/03 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CStone Pharmaceuticals is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
null nullGuoyuan Securities (HK) Ltd
Hanyang HuangIndustrial Securities Co. Ltd.